Oncology had the most approvals at 13, or about 24% of the total. This included several notable first-in-class therapies like AstraZeneca’s AKT inhibitor capivasertib for certain breast cancers, Springworks’ gamma-secretase inhibitor nirogacestat for desmoid tumors, and J&J’s G...